{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:00:09Z","timestamp":1783702809345,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-024-02653-7","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:02:50Z","timestamp":1727852570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term (24\u00a0weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"given":"Yuan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"issue":"9988","key":"2653_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo Lancet. 2015;386(9988):74\u201384.","journal-title":"Vitiligo Lancet"},{"issue":"6","key":"2653_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1159\/000506103","volume":"236","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571\u201392.","journal-title":"Dermatology"},{"issue":"10","key":"2653_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51(10):1206\u201312.","journal-title":"Int J Dermatol"},{"key":"2653_CR4","doi-asserted-by":"crossref","unstructured":"Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473\u2013491.","DOI":"10.1016\/j.jaad.2010.11.061"},{"issue":"9","key":"2653_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163806","volume":"11","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Cai Y, Shi M, et al. The Prevalence of Vitiligo: A Meta-Analysis. PLoS ONE. 2016;11(9): e0163806.","journal-title":"PLoS ONE"},{"issue":"3","key":"2653_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0378-6323.32708","volume":"73","author":"VN Sehgal","year":"2007","unstructured":"Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149\u201356.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2653_CR7","doi-asserted-by":"crossref","unstructured":"Elbuluk N, Ezzedine K. Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo\u00a0Patients. Dermatol Clin. 2017;35(2):117\u2013128. Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u20131844.","DOI":"10.1016\/j.det.2016.11.002"},{"issue":"2","key":"2653_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1034\/j.1600-0749.2003.00023.x","volume":"16","author":"K Ongenae","year":"2003","unstructured":"Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90\u2013100.","journal-title":"Pigment Cell Res"},{"key":"2653_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","volume":"12","author":"F Qi","year":"2021","unstructured":"Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021;12: 790125.","journal-title":"Front Immunol"},{"issue":"16","key":"2653_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445\u201355.","journal-title":"N Engl J Med"},{"issue":"10244","key":"2653_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"key":"2653_CR12","doi-asserted-by":"crossref","unstructured":"Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 78(6):1205\u20131207.e1.","DOI":"10.1016\/j.jaad.2018.02.023"},{"key":"2653_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jclinepi.2020.05.019","volume":"125","author":"Y Gao","year":"2020","unstructured":"Gao Y, Yang K, Cai Y, et al. Updating systematic reviews can improve the precision of outcomes: a comparative study. J Clin Epidemiol. 2020;125:108\u201319.","journal-title":"J Clin Epidemiol"},{"key":"2653_CR14","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook."},{"key":"2653_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2653_CR16","unstructured":"Guyatt GH, Busse JW. Modification of Cochrane tool to assess risk of bias in randomized trials. https:\/\/www.evidencepartners.com\/resources\/methodological-resources\/."},{"issue":"7650","key":"2653_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"2653_CR18","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011;64(4): 407\u2013415.","DOI":"10.1016\/j.jclinepi.2010.07.017"},{"key":"2653_CR19","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12): 1283\u20131293.","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"2653_CR20","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12): 1294\u20131302.","DOI":"10.1016\/j.jclinepi.2011.03.017"},{"key":"2653_CR21","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011;64(12): 1303\u20131310.","DOI":"10.1016\/j.jclinepi.2011.04.014"},{"key":"2653_CR22","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12): 1277\u20131282.","DOI":"10.1016\/j.jclinepi.2011.01.011"},{"key":"2653_CR23","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","volume":"1","author":"M Picardo","year":"2015","unstructured":"Picardo M, Dell\u2019Anna ML, Ezzedine K, et al. Vitiligo Nat Rev Dis Primers. 2015;1:15011.","journal-title":"Vitiligo Nat Rev Dis Primers"},{"issue":"8","key":"2653_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/ced.12443","volume":"40","author":"S Shin","year":"2015","unstructured":"Shin S, Shin JY, Lee H, et al. Spreading of pre-existing segmental vitiligo after immunotherapy with house dust mite in a patient with atopic dermatitis. Clin Exp Dermatol. 2015;40(8):920\u20131.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2653_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.20596","volume":"186","author":"V Eleftheriadou","year":"2022","unstructured":"Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18\u201329.","journal-title":"Br J Dermatol"},{"issue":"6","key":"2653_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","volume":"18","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert R, van Geel N. Vitiligo: An Update on Pathophysiology and Treatment Options. Am J Clin Dermatol. 2017;18(6):733\u201344.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2653_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","volume":"24","author":"KN Cunningham","year":"2023","unstructured":"Cunningham KN, Rosmarin D. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. Am J Clin Dermatol. 2023;24(2):165\u201386.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2653_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","volume":"149","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159\u201364.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2653_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-4632.2011.04932.x","volume":"51","author":"SM Wong","year":"2012","unstructured":"Wong SM, Baba R. Quality of life among Malaysian patients with vitiligo. Int J Dermatol. 2012;51(2):158\u201361.","journal-title":"Int J Dermatol"},{"issue":"6","key":"2653_CR30","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/bjd.15933","volume":"177","author":"B Morrison","year":"2017","unstructured":"Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338\u20139.","journal-title":"Br J Dermatol"},{"key":"2653_CR31","doi-asserted-by":"crossref","unstructured":"Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Ann Pharmacother. 2022: 10600280221143748.","DOI":"10.1177\/10600280221143748"},{"key":"2653_CR32","doi-asserted-by":"crossref","unstructured":"Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023; 0: 1\u20139.","DOI":"10.1111\/jdv.19162"},{"issue":"7","key":"2653_CR33","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/pharmaceutics13071044","volume":"13","author":"P Smith","year":"2021","unstructured":"Smith P, Yao W, Shepard S, et al. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics. 2021;13(7):1044.","journal-title":"Pharmaceutics"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-024-02653-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-024-02653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:04:54Z","timestamp":1727852694000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-024-02653-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2653"],"URL":"https:\/\/doi.org\/10.1186\/s13643-024-02653-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3171294\/v1","asserted-by":"object"}]},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}